Anti-biofilm therapies using local application of bacteriophages (ANTIBIO-LAB)

The use of medical devices has had an enormously positive impact on patient care. However, approximately 5% of patients across all medical specialities can develop an infection associated with the device, which can have disastrous consequences.

Ongoing project

These bacterial infections involve biofilm formation and are therefore always highly antibiotic tolerant, even in the absence of specific antibiotic resistance genes. The antibiotic recalcitrance of the biofilm leads to poor treatment success rates and often requires implant removal to treat the infection.

The ANTIBIO-LAB consortium’s overall aim is to introduce a new concept in the treatment of antibiotic resistant biofilm infections by delivering biofilmadapted bacteriophages in a customised local delivery vehicle. The methods that we will employ draw from our collective experience in phage isolation, phage in vitro evolution, local delivery vehicle design, and clinically relevant in vitro and in vivo models of biofilm infection.

 

Project partners

  • Fintan Moriarty, AO Research Institute Davos, Switzerland (Coordinator)
  • Andrej Trampuz, Universitätsmedizin Berlin, Germany
  • Willem-Jan Metsemakers, University Hospitals Leuven, Belgium
  • David Eglin, AO Research Institute Davos, Switzerland
  • Rob Lavigne, Université Catholique de Louvain, Belgium
  • Mariagrazia Di Luca, PRO-IMPLANT Foundation, Germany